Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

597
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
597
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship01:29

Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship

522
Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
522
Indirect-Acting Cholinergic Agonists: Mechanism of Action01:18

Indirect-Acting Cholinergic Agonists: Mechanism of Action

1.7K
Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
1.7K
Enzymes02:34

Enzymes

80.8K
Inside living organisms, enzymes act as catalysts for many biochemical reactions involved in cellular metabolism. The role of enzymes is to reduce the activation energies of biochemical reactions by forming complexes with its substrates. The lowering of activation energies favor an increase in the rates of biochemical reactions.
Enzyme deficiencies can often translate into life-threatening diseases. For example, a genetic abnormality resulting in the deficiency of the enzyme G6PD...
80.8K
Ligand Binding and Linkage00:49

Ligand Binding and Linkage

4.8K
Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked.  In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence...
4.8K
Enzyme Inhibition01:30

Enzyme Inhibition

77.9K
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
77.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Mechanism of moxibustion at the governor vessel for regulating autophagy against Alzheimer's disease via lncRNA-RP4-mediated Wnt/β-catenin pathway].

Zhongguo zhen jiu = Chinese acupuncture & moxibustion·2026
Same author

Molecular basis for the dopamine reuptake and inhibition mechanism of human dopamine transporter.

Structure (London, England : 1993)·2026
Same author

Network Pharmacology and Experimental Verification to Explore Cinnamomi Cortex against Steroid-induced Osteonecrosis of the Femoral Head.

Journal of visualized experiments : JoVE·2026
Same author

Spatiotemporal Engineering for the Synthesis of Multi-Scale Turing-Patterned High-Entropy Alloys.

Advanced materials (Deerfield Beach, Fla.)·2026
Same author

Efficient 96-Well Plate Conjugation of Unnatural Amino Acid Building Blocks to DNA for DNA-Encoded Library Applications.

Bioconjugate chemistry·2026
Same author

Mapping supportive-care evidence for febrile neutropenia prevention in breast cancer chemotherapy: a bibliometric analysis of long-acting G-CSF prophylaxis.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2026

Related Experiment Video

Updated: Jun 7, 2025

Deacetylation Assays to Unravel the Interplay between Sirtuins SIRT2 and Specific Protein-substrates
14:32

Deacetylation Assays to Unravel the Interplay between Sirtuins SIRT2 and Specific Protein-substrates

Published on: February 27, 2016

8.2K

Mechanism-based inactivators of sirtuin 5: A focused structure-activity relationship study.

Tobias N Hansen1, Xinyi Yuan1, Marc S I Santana1

  • 1Center for Biopharmaceuticals & Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Jagtvej 160, DK-2100 Copenhagen, Denmark.

Bioorganic & Medicinal Chemistry Letters
|November 9, 2024
PubMed
Summary

Researchers identified potent Sirtuin 5 (SIRT5) inhibitors, acting as mechanism-based inactivators. Prodrugs were developed to target SIRT5 within cells, offering potential for cancer therapies.

Keywords:
Enzyme inhibitorsEnzyme kineticsMechanism-based inactivationPosttranslational modificationSIRT5Sirtuins

More Related Videos

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

426
Vasodilation of Isolated Vessels and the Isolation of the Extracellular Matrix of Tight-skin Mice
08:09

Vasodilation of Isolated Vessels and the Isolation of the Extracellular Matrix of Tight-skin Mice

Published on: March 24, 2017

8.0K

Related Experiment Videos

Last Updated: Jun 7, 2025

Deacetylation Assays to Unravel the Interplay between Sirtuins SIRT2 and Specific Protein-substrates
14:32

Deacetylation Assays to Unravel the Interplay between Sirtuins SIRT2 and Specific Protein-substrates

Published on: February 27, 2016

8.2K
Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

426
Vasodilation of Isolated Vessels and the Isolation of the Extracellular Matrix of Tight-skin Mice
08:09

Vasodilation of Isolated Vessels and the Isolation of the Extracellular Matrix of Tight-skin Mice

Published on: March 24, 2017

8.0K

Area of Science:

  • Biochemistry
  • Enzymology
  • Medicinal Chemistry

Background:

  • Sirtuin 5 (SIRT5) is a lysine deacylase enzyme.
  • SIRT5 removes specific posttranslational modifications.
  • SIRT5 inhibition is a potential therapeutic strategy for leukemia and breast cancer.

Purpose of the Study:

  • To conduct a structure-activity relationship study to identify potent SIRT5 inhibitors.
  • To characterize the mechanism of action of identified inhibitors.
  • To develop prodrugs for cellular SIRT5 targeting.

Main Methods:

  • Focused structure-activity relationship analysis.
  • Kinetic evaluation of enzyme inhibitors.
  • Prodrug design and cellular binding assays.

Main Results:

  • Identification of highly potent SIRT5 inhibitors.
  • Demonstration of mechanism-based inactivation by inhibitors.
  • Development of prodrugs that bind SIRT5 in cells.

Conclusions:

  • Kinetic characterization is crucial for enzyme inhibitor development.
  • Optimized SIRT5 inhibitors show promise for in vivo applications.
  • This study provides a foundation for developing novel cancer therapeutics targeting SIRT5.